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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A401Fig 1. Histological Grading of the IFP and SYN (Mean þ/- SD). Bar ¼
statistical difference from group comparison. * ¼ Single IA administration
of DEX signiﬁcantly lowered the histological grade in direct comparison
between Drill and DrillþDEX.
Fig 2. Cartilage Histology (Mean þ/- SD). Bar ¼ statistical difference from
group comparison. * ¼ Single IA administration of DEX signiﬁcantly
lowered the histological grade in direct comparison between Drill and
DrillþDEX.
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INJECTION OF EXTRACELLULAR MATRIX GEL FOLLOWING ANTERIOR
CRUCIATE LIGAMENT INJURY MITIGATES OSTEOARTHRITIC CHANGES
IN A RAT MODEL
B.L. Proffen y, J.T. Sieker y, M.M. Murray y, K.E. Chin z, T.K. Patel z,
E. Robbins z, M.R. Akelman z, J.T. Machan x, B.C. Fleming z. yBoston
Children's Hosp., Harvard Med. Sch., Boston, MA, USA; zWarren Alpert
Med. Sch. of Brown Univ./Rhode Island Hosp., Providence, RI, USA;
xRhode Island Hosp., Providence, RI, USA
Purpose: To investigate whether the development of post-traumatic
osteoarthritis (PTOA) is prevented or modulated in a rat model of
anterior cruciate ligament (ACL) injury following a single intraarticular
injection of an extracellular matrix (ECM) gel/autologous whole blood
composite at day 0 or 14 after ACL injury.
Methods: ECM gels were prepared according to good-laboratory-
practice guidelines from bovine source ECM. Thirty-two Lewis rats
underwent unilateral ACL transection and either subsequent intra-
articular injection of ECM gel/autologouswhole blood composite on day
0 (n¼11 rats, INJ0 group) or day 14 (n¼11 rats, INJ14 group) or nofurther treatment (n¼10, ACLT group), while ten additional animals
received capsulotomy but no ACL transection (n¼10, SHAM group).
Before and 35 days after surgery gait analysis was performed using a
pressure sensing walkway, followed by euthanasia and the assessment
of PTOA-related phenotypes in cartilage, subchondral bone and synovial
tissue. Speciﬁcally, histological scoring was performed according to the
recommendations of the OARSI histopathology initiative, while the
subchondral bone-mineral density was assessed using micro-computed
tomography (micro-CT). The ratio of intact contralateral/treated hind
limb maximum applied forces, was calculated for the pre-surgery and 5
weeks post-surgery timepoints. Then the difference of the pre and post-
surgery ratios were compared between the groups. Further the differ-
ences of intact contralateral and treated tibial subchondral bone-min-
eral density (mg hydroxyappatit/cm^3), as well as the tibial OARSI
histological scores of the treated knees were compared between the
groups using a one-way analysis of variance with post-hoc Bonferroni
test for normally distributed and Kruskal Wallis test with Dunn post-
hoc test for non-normally distributed data. Adjusted p values < 0.05
were considered statistically signiﬁcant.
Results:Weight bearing on the operated limb was decreased by 15% in
the ACLT group ﬁve weeks after surgery (P<0.05), while rats in INJ0 and
INJ14 groups had only non-signiﬁcant 3% and 10% decrease from their
preoperative baseline values, respectively (P¼0.44 and 0.18). All groups
that have received ACLT regardless of the consecutive treatment dem-
onstrated a loss of bone mineral density, with a loss of 99.7 mg/cm^3
(95% CI 81.4, 117.9; P<0.001) in the ACLT, 115.1 mg/cm^3 (95% CI 85.1,
145.0; P<0.001) in the INJ0, and 93.8 (95% CI 72.3, 115.3; P<0.001) in the
INJ14 group, which was signiﬁcant in the comparison to the SHAM
group, that did not demonstrate a loss of bone-mineral density (-4.6mg/
cm^3; 95% CI -21.4, 12.3). In the histological assessment, the cartilage
degeneration sum score was statistically signiﬁcantly worse in the ACLT
group (7.5, 95% CI 7.0, 8.0) than in the SHAM (5.0, 95% CI 4.0, 6.0, P<
0.001), INJ0 (6.1, 95% CI 5.3; 6.9, P¼0.031), and INJ14 group (6.0, 95% CI
5.3, 6.7; P¼0.022), while the difference of INJ0 and INJ14 from SHAM
was not considered statistically signiﬁcant (P¼ 0.161 and 0.276,
respectively). In the histological assessment of the synovium, no sig-
niﬁcant differences between the ACLT (2.6, 95% CI 2.0, 3.2) and the INJ0
(2.5, 95% CI 1.7, 3.4; P¼1.0) or the INJ14 (3.1, 95% CI 2.7, 3.5; P¼0.957)
groups were detected in the histological synovial inﬂammation score,
which were all signiﬁcantly worse (all P<0.001) than SHAM (0.9, 95% CI
0.4, 1.4).
Conclusions: Injection of ECM gel/autologous whole blood composite
reduced damage of cartilage surface after ACL transection, and resulted
in fewer changes in gait asymmetry. However, the treatment did not
prevent subchondral bone-mineral-loss or synovial inﬂammation. Early
or delayed injection of ECM gel/autologous whole blood composite
modulates the development of PTOA after ACL transection in a rat
model, particularly in regards to the cartilage surface and joint function.
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EARLY INTRAARTICULAR TRIAMCINOLONE ACETONIDE
ADMINISTRATION ALTERS ANTERIOR CRUCIATE LIGAMENT INJURY-
INDUCED CHANGES IN SYNOVIAL MEMBRANE GENE EXPRESSION
J.T. Sieker y, U.M. Ayturk y, B.L. Proffen y, B.C. Fleming z, M.M. Murray y.
yBoston Children's Hosp., Harvard Med. Sch., Boston, MA, USA; zWarren
Alpert Med. Sch., Brown Univ. and Rhode Island Hosp., Providence, RI, USA
Purpose: First, to deﬁne early alterations in gene expression (genes and
pathways) within synovial membranes of a porcine post-traumatic
osteoarthritis [PTOA] model. Second, to assess the efﬁcacy of intra-
articular triamcinolone acetonide to attenuate the synovial membrane’s
response to the surgical anterior cruciate ligament [ACL] injury.
Methods: Eighteen minipigs (meanweight of 33.4 kg) were allocated to
unilateral ACL transection [ACLT] alone, unilateral ACLT and immediate
injection of 20mg triamcinolone acetonide, or no surgery (n ¼ 6 each
group). At 14 days after ACLT, synovial membranes were harvested and
used for RNA-sequencing (RNA-seq) to quantify transcriptome wide
gene expression changes. Raw reads were mapped to the pig genome
(Susscr3, released Aug. 2011) with the RNA-seq uniﬁed mapper (RUM)
pipeline. Reads uniquely aligned to the exons of each gene were
counted with a custom R script that utilizes Rsamtools and Genomics-
Features packages, and used for differential expression analysis with the
edgeR package. P-values were then corrected using a Benjamini &
Hochberg approach to adjust for multiple hypothesis testing to adjust
for the transcriptome-wide analysis. A ﬁlter was applied to exclude very
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million mapped reads in both of the compared groups), as changes in
those transcripts are prone to overestimation. Changes in expression
levels were considered signiﬁcant if the adjusted p was < 0.05 and
remained below that threshold when leaving out one sample at a time
(sample-speciﬁc leave-one-out cross validation). The MetaCore Soft-
ware suite (Thomson & Reuters, New York) was used to assess if the
differentially expressed genes enrich terms (pathways) of the propri-
etary process network ontology. Pathway enrichment was considered
as signiﬁcant if the false-discovery-rate was < 0.10 and the enrichment
was due to > 2 different genes. The reproducibility of those changes was
assessed using a second independent dataset of the porcine model (n ¼
12 intact and n ¼ 6 ACLT). Histomorphometry was performed to
quantify changes in synovial membrane cellularity.
Results: 81 protein-coding genes and 7 pathways, including changes
related to Wnt signaling (i.e. upregulation of SFRP2), chemotaxis (i.e.
upregulation of CCL21), cell adhesion and proliferation, proteolysis (i.e.
upregulation of MMP1 and MMP2), as well as blood vessel morpho-
genesis and the regulation thereof, were reproducibly altered at 14 days
after ACLT when compared with joints that did not receive surgery.
Concomitantly the synovial membrane cellularity increased two-fold (p
< 0.001) in response to the surgical injury. Early triamcinolone injection
after ACLT signiﬁcantly altered the expression of 33 protein-coding
genes in the transcriptome-wide analysis, when compared to joints that
received ACLT without further treatment. These differentially expressed
genes signiﬁcantly enriched 3 ontology terms, all of which are related to
chemotaxis. Speciﬁcally, early triamcinolone treatment modiﬁed che-
motaxis-related changes in gene expression by inducing an upregula-
tion of ACKR4 and CXCL6, as well as a downregulation of CX3CR1,
without substantially modulating the cellularity (p ¼ 0.980).
Conclusions: The assessment of early changes within the synovial
membrane, a tissue that is involved in the pathogenesis of PTOA,
revealed potential new targets for early disease-modifying inter-
ventions, such as those related to Wnt signaling (SFRP2) or immuno-
modulation (CCL21, ACKR4). One potential agent is triamcinolone
acetonide, which altered gene expression patterns, particularly for the
chemotaxis pathway, but failed tomodulate the histological phenotype.
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DETERMINANTS OF LONG TERM TREATMENT RESPONSE FOLLOWING
INTRA-ARTICULAR STEROID THERAPY IN KNEE OA
T.W. O'Neill y, M.J. Parkes y, N. Maricar y, D.T. Felson z. y The Univ. of
Manchester, Manchester, United Kingdom; zBoston Univ., Boston, MA, USA
Purpose: Intra-articular steroids are an effective therapy in the man-
agement of pain in symptomatic knee osteoarthritis (OA). Data from
meta-analysis suggests that therapy is effective for up to 2 weeks fol-
lowing steroid injection with at least two large trials suggesting longer
term beneﬁt. An understanding of factors linked with longer term
response would help in targeting therapy at those who may most
beneﬁt. The aim of this analysis was to assess determinants of long term
(6 months) response to therapy.
Methods: 120 men and women with painful knee osteoarthritis, and
who met ACR criteria for the disease, were recruited for participation
in an open label clinical trial of intra-articular steroid therapy. Sub-
jects who took part in the study had signiﬁcant knee pain and either
grade 2 or higher knee OA on knee x-ray or evidence of OA on
arthroscopy or magnetic resonance imaging (MRI). At baseline sub-
jects completed the KOOS questionnaire, a Visual Analogue Scale for a
nominated activity (VASNA), the hospital anxiety and depression
inventory (HAD), the short form-12 questionnaire and the brief Illness
perception questionnaire (IPQ-B). They also had a contrast enhanced
MRI performed, from which the total bone marrow lesion (BML)
volume (mm3) and synovial tissue (ST) volume (mm3) were deter-
mined. Subjects received an injection of intra-articular depomedrone
(80mg). They were seen within 2 weeks of injection and response
assessed using the OARSI-OMERACT responder criteria. Those who
responded were followed by serial telephone call until their knee
pain recurred (within 20% of their baseline level of pain) or 6 months
at which point the trial was stopped. Logistic regression was used to
determine the factors associated with long term response to therapy
with the results expressed as odds ratios (OR) and 95% conﬁdence
intervals (CI).Results: The mean age of subjects who were recruited was 62.3 (SD
10.3) and 62 (51.6%) were female. The median time between baseline
and follow up scanwas 8 days (IQR 7 to 14 days). 85 (70.8%) were initial
responders and these subjects were then followed up by telephone.
After 6 months 23 (19.2%) out of the original cohort had still not
returned towithin 20% of their baseline level of knee pain. Compared to
those whose pain either did not respond, or who were initial res-
ponders and whose pain recurred within 6 months, persistent res-
ponders were less likely to be anxious OR ¼ 0.85 (95% CI 0.73 to 0.99),
depressed OR¼0.72 (95% CI 0.57 to 0.91) and to have a lower IPQ-B score
OR¼0.95 (95% CI 0.91 to 1.00). Neither pain assessed using KOOS or
VASNA, health related Quality of Life assessed by the SF12, or the MRI
parameters (BML & ST volume) predicted long term response. In a
multivariate model only depression score OR¼0.66 (95%CI 0.45, 0.96)
remained signiﬁcant.
Conclusions: In this open label study, almost one ﬁfth of men and
women with symptomatic knee osteoarthritis had long term beneﬁcial
reductions in pain following steroid therapy. Lower levels of depressive
symptoms are linked with long term response.
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INTRA-ARTICULAR DELIVERY OF KARTOGENIN-CONJUGATED
CHITOSAN NANO/MICROPARTICLES FOR CARTILAGE REGENERATION
G.-I. Im, M. Kang, J.-Y. Ko, J. Kim. Dongguk Univ. Int'l Hosp., Goyang,
Republic of Korea
Purpose: Osteoarthritis (OA), also known as degenerative arthritis or
degenerative joint disease, affects millions of people around the world.
Intra-articular (IA) drug delivery can be a useful modality in OA
treatment, delivering a drug directly to the main focus of the disease.
The therapeutic effect of IA drug depends mostly on the efﬁcacy of the
drug delivery system, due to the short retention time and rapid
clearance of soluble drugs from the joint. Kartogenin is a recently
characterized material that promotes the selective differentiation of
mesenchymal stem cells (MSCs) into chondrocytes, thus stimulating
cartilage regeneration. We developed an intra-articular (IA) drug
delivery system to treat osteoarthritis (OA) that consisted of kartoge-
nin conjugated chitosan (CHI-KGN). The aim of this study was to (1)
characterize the CHI-KGN particles for sustained release and chon-
drogenic activity in vitro, (2) evaluate the CHI-KGN particles as novel IA
drug delivery systems for IA retention and regeneration of OA joint in
vivo.
Methods: Kartogenin was conjugated with low-molecular-weight
chitosan (LMWCS) and medium-molecular-weight chitosan (MMWCS)
by covalent coupling of kartogenin to each chitosan using an ethyl(-
dimethylaminopropyl)carbodiimide (EDC)/N-hydroxysuccinimide
(NHS) catalyst. The particular drug delivery systems were prepared by
an ionic gelation of the CHI-KGN conjugate with tripolyphosphate
(TPP) anion that can interact with cationic chitosan by electrostatic
forces.
Results: Nanoparticles (NPs, 150±39 nm) or microparticles (MPs,
1.8±0.54 mm) were successfully fabricated from kartogenin conjugated-
LMWCS and -MMWCS, respectively, by an ionic gelation using TPP. The
in vitro release proﬁles of kartogenin from the particles showed sus-
tained release for 7 weeks. When the effects of the CHI-KGN NPs or CHI-
KGN MPs were evaluated on the in vitro chondrogenic differentiation of
human bone marrowMSCs (hBMMSCs), the CHI-KGN NPs and CHI-KGN
MPs induced higher expression of chondrogenic markers from cultured
hBMMSCs than unconjugated kartogenin. In particular, hBMMSCs
treated with CHI-KGN NPs exhibited more distinct chondrogenic
properties in the long-term pellet cultures than those treated with CHI-
KGN MPs. The in vivo therapeutic effects of CHI-KGN NPs or CHI-KGN
MPs were investigated using a surgically-induced OA model in rats. The
CHI-KGN MPs showed longer retention time in the knee joint than the
CHI-KGN NPs after IA injection in OA rats. The rats treated with CHI-
KGN NPs or CHI-KGN MPs by IA injection showed much less degener-
ative changes than untreated control or rats treated with unconjugated
kartogenin.
Conclusions: In conclusion, CHI-KGN NPs or CHI-KGN MPs can be
useful polymer-drug conjugates for an IA drug delivery system to treat
OA.
